B.I.G. VISION® FOR ALL from Rodenstock: Optimal vision with biometric lenses for everyone
MUNICH, April 4, 2022 /PRNewswire/ -- Everyone's appearance is so different and individual and so too are their eyes. Rodenstock recognised that every eye is different and developed an innovative technology that determines the personal biometrics of the eye from several thousand measuring points and incorporates these results directly into the manufacture...
Radiaction Medical Ltd. Receives FDA Clearance for its Innovative Radiation Protection System and Secures $10M for US Launch and Commercialization
TEL AVIV, Israel, April 4, 2022 /PRNewswire/ -- Radiaction Medical Ltd. ("Radiaction"), an innovative medical device company focused on radiation protection in the interventional cardiology and electrophysiology sectors, announced FDA 510(K) clearance for the marketing of its Shield System in the US. In addition, the company has completed a $10 million round of financing led by current investors, InnovaHealth...
Telix, GMS and Monash Awarded $23M Federal Government Funding as part of $71M Australian Precision Medicine Enterprise (APME) Project
MELBOURNE, Australia, April 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that it is part of a $71.2 million Australian Precision Medicine Enterprise (APME) Project, which has been awarded $23 million in Federal Government grant funding under the Manufacturing Collaboration Stream of the Modern Manufacturing Initiative (MMI)....
CanSinoBIO’s COVID-19 mRNA Vaccine Receives Approval of Clinical Trial Application in China
TIANJIN, April 4, 2022 /PRNewswire/ -- CanSino Biologics Inc. ("CanSinoBIO" of "the Company") (SSE: 688185, HKEX: 06185) today announced that the National Medical Products Administration of China ("NMPA") granted approval for the clinical trial application of its COVID-19 mRNA vaccine in China. Pre-clinical trial results showed that CanSinoBIO's COVID-19 mRNA vaccine can induce high-titer neutralizing antibody levels against...
Innovent Releases Results of a Phase 3 Clinical Study of IBI306 (PCSK-9 inhibitor) in Chinese Patients with Heterozygous Familial Hypercholesterolemia at the American College of Cardiology Annual Congress 2022
SAN FRANCISCO and SUZHOU, China, April 4, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the results of a phase 3 clinical trial (Study code: CREDIT-2) of recombinant full-human anti-PCSK-9 monoclonal antibody (R&D...
Commercial Launch: Illuccix® Now Available to Order in the United States
MELBOURNE, Australia and INDIANAPOLIS, April 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) announces that its prostate cancer imaging agent, Illuccix® (kit for preparation of gallium Ga 68 gozetotide), also known as 68Ga-PSMA-11 injection, is now commercially available in the United States. Illuccix is available to order from 117...
Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong
HANGZHOU and SHAOXING, China, April 3, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today announces that it has submitted the marketing authorization application for ritonavir (100 mg film-coated tablet) in the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong"). Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 9) released on...
JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China
SHANGHAI, April 3, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China granted Breakthrough Therapy Designation for Carteyva® (relmacabtagene autoleucel injection) in patients with mantle cell lymphoma (MCL). Carteyva® is an...
Dada’s JDDJ in action to guarantee medical supply and online health consultation with pharmaceutical partners
SHANGHAI, April 2, 2022 /PRNewswire/ -- As a number of cities in China are ramping up anti-epidemic measures, more consumers rely on online-to-offline services to purchase much-needed medications. JDDJ, one of China's largest local on-demand retail platforms operated by Dada Group (Nasdaq: DADA), is proactively stepping up efforts to guarantee citizens' medication needs in collaboration with its pharmaceutical partners. ...
Peijia Medical Announces 2021 Annual Results
Dual Engines Promote Commercialization Total Revenue Increased by 253.2% HONG KONG, April 2, 2022 /PRNewswire/ -- Peijia Medical Limited ("Peijia Medical" or the "Company", together with its subsidiaries, the "Group", stock code: 9996), a leading player in the high-growth transcatheter valve therapeutic and neurointerventional procedural medical device markets in China, announced its audited...
